FOXP3 and atherosclerosis: Using a new mouse model of atherosclerosis regression in Ldlr−/−, we found that Eicosapentaenoic acid induced atherosclerosis regression by modulating DC functions and reducing CD4+ T cell numbers without increasing CD4+CD25+Foxp3+ Tregs [132], supporting the clinical benefits of this drug for the treatment of CVD in Japanese hypercholesterolemic patients [133].